Phytanic acid 

Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease^{[1][2][3][4][5]}.

Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

312.53

C₂₀H₄₀O₂

14721-66-5

Liquid

Colorless to light yellow

CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O

Room temperature in continental US; may vary elsewhere.

Solution, -20°C, 2 years

• [1]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720.  [Content Brief]

  [2]. Budden SS, et al. Dysmorphic syndrome with phytanic acid oxidase deficiency, abnormal very long chain fatty acids, and pipecolic acidemia: studies in four children. J Pediatr. 1986 Jan;108(1):33-9.  [Content Brief]

  [3]. McLean BN, et al. A new defect of peroxisomal function involving pristanic acid: a case report. J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):396-9.  [Content Brief]

  [4]. Baumgartner MR, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol. 1998 Nov;44(5):720-30.  [Content Brief]

  [5]. Poll-The BT, et al. Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction. J Inherit Metab Dis. 1986;9(2):169-74.  [Content Brief]